Distinguished in Hepatitis B

Guofeng Z. Chen

Beijing, CN 
Distinguished in Hepatitis B
Beijing, CN 
OverviewLocationsClinical Research

Overview

Guofeng Chen practices in Beijing, China. Chen is rated as a Distinguished expert by MediFind in the treatment of Hepatitis B. Their top areas of expertise are Hepatitis B, Hepatitis, Cirrhosis, Hepatitis C, and Kidney Transplant.

Their clinical research consists of co-authoring 37 peer reviewed articles and participating in 9 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 21 articles and participated in 4 clinical trials in the study of Hepatitis B.

Locations

Beijing, China

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

Efficacy and Safety of Switching From Pegylated Interferon/Ribavirin (PR) to Direct-acting Antiviral Agents (DAAs) for Chinese With CHC Genotype 1b Infection (SWITCH-1)
Efficacy and Safety of Switching From Pegylated Interferon/Ribavirin (PR) to Direct-acting Antiviral Agents (DAAs) for Chinese With CHC Genotype 1b Infection (SWITCH-1)
Enrollment Status: Completed
Publish Date: March 26, 2025
Intervention Type: Drug
Study Drugs: PR4+Ledipasvir/sofosbuvir+Asunaprevir, PR4+Ledipasvir/sofosbuvir+Simeprevir
Study Phase: Phase 2
Long Term Follow-up for Subjects With Chronic Hepatitis C Infection Who Received Interferon-based Therapy or Direct-acting Antiviral Agents (DAAs)-Based Therapy
Long Term Follow-up for Subjects With Chronic Hepatitis C Infection Who Received Interferon-based Therapy or Direct-acting Antiviral Agents (DAAs)-Based Therapy
Enrollment Status: Completed
Publish Date: March 24, 2025
Effect of Entecavir Treatment on Regression and Long-term Disease Outcome in Patients With HBV-induced Liver Fibrosis and Cirrhosis (Regress Extension Study)
Effect of Entecavir Treatment on Regression and Long-term Disease Outcome in Patients With HBV-induced Liver Fibrosis and Cirrhosis (Regress Extension Study)
Enrollment Status: Active_not_recruiting
Publish Date: April 28, 2021
Intervention Type: Drug
Study Drug: Entecavir
Study Phase: Phase 4
Optimized Treatment and Regression of HBV-induced Liver Fibrosis
Optimized Treatment and Regression of HBV-induced Liver Fibrosis
Enrollment Status: Completed
Publish Date: July 27, 2018
Intervention Type: Drug
Study Phase: Phase 4
Optimized Treatment and Regression of HBV-induced Early Cirrhosis
Optimized Treatment and Regression of HBV-induced Early Cirrhosis
Enrollment Status: Completed
Publish Date: July 27, 2018
Intervention Type: Drug
Study Phase: Phase 4
Optimized Treatment and Regression of HBV-induced Compensated Liver Cirrhosis
Optimized Treatment and Regression of HBV-induced Compensated Liver Cirrhosis
Enrollment Status: Completed
Publish Date: July 27, 2018
Intervention Type: Drug
Study Phase: Phase 4
Efficacy and Safety Study of Sofosbuvir Containing Regimens in Subjects With Chronic Hepatitis C Virus Genotype 3 Infection
Efficacy and Safety Study of Sofosbuvir Containing Regimens in Subjects With Chronic Hepatitis C Virus Genotype 3 Infection
Enrollment Status: Completed
Publish Date: March 19, 2018
Intervention Type: Drug
Study Phase: Phase 3
Efficacy and Safety Study of Sofosbuvir Containing Regimens in Subjects With Chronic Hepatitis C Virus Genotype 2 Infection
Efficacy and Safety Study of Sofosbuvir Containing Regimens in Subjects With Chronic Hepatitis C Virus Genotype 2 Infection
Enrollment Status: Completed
Publish Date: March 19, 2018
Intervention Type: Drug
Study Phase: Phase 4
Efficacy and Safety of Sofosbuvir Plus Daclatasvir in Chinese Treatment-experienced Patients With Chronic Genotype 1b HCV Infection
Efficacy and Safety of Sofosbuvir Plus Daclatasvir in Chinese Treatment-experienced Patients With Chronic Genotype 1b HCV Infection
Enrollment Status: Completed
Publish Date: March 19, 2018
Intervention Type: Drug
Study Phase: Phase 2/Phase 3
View 8 Less Clinical Trials

37 Total Publications

Early on-treatment LSM reliably predicts liver-related events in CHB patients with significant fibrosis and cirrhosis.
Early on-treatment LSM reliably predicts liver-related events in CHB patients with significant fibrosis and cirrhosis.
Journal: Hepatology (Baltimore, Md.)
Published: March 03, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Chen's expertise for a condition
ConditionClose
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile